Clinical trials: Lp(A)
Hyperlipidemias, Dyslipidemias
Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)
This study will investigate the safety and tolerability of SLN360 in patients with elevated Lp(a).
- Conditions
- Hyperlipidemias, Dyslipidemias, Elevated Lp(a)
- Trial name
- NCT04606602
- Testing
- SLN360
- Where
- 8 sites in United States, Australia and 2 more
- Volunteers
- 70 people
- Sponsor
- Silence Therapeutics plc
Implementing EAS/ESC Guideline Recommendation on Lp(a) Testing in Routine Practice
Impact of Implementation Strategies on Lp(a) Testing in Secondary Care Settings
Lipoprotein(a) [Lp(a)] is recognised as an independent, non-modifiable genetic risk factor for cardiovascular (CV) disease. Current guidelines from the European Society of Cardiology (ESC) and the European Atherosclerosis Society…
- Trial name
- Lp(a)CCELERATE (NCT07508007)
- Where
- Germany
- Volunteers
- 4,500 people
- Sponsor
- Novartis Pharmaceuticals
Recurrent Medulloblastoma
RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)
The primary objective will be to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in pediatric patients with recurrent/progressive Medulloblastoma (MB)
- Trial name
- PNOC020 rMB (NCT07492316)
- Testing
- Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Florida
Acromegaly
Somatostatin Analog Treatment of Acromegaly Before Pituitary Surgery : Comparison With Neurosurgery Alone
The aim of the study is to evaluate the interest of a six month pre-operative treatment with a long-acting somatostatin analog (Sandostatin LP) versus surgery alone in patients with a pituitary adenoma responsible for acromegaly.
- Trial name
- SAPORO (NCT01029275)
- Testing
- Pre-treatment with octreotide
- Where
- 13 sites in France
- Volunteers
- 89 people
- Sponsor
- University Hospital, Rouen
Intestinal Growth of Young Children
A Study on Efficacy of Feeding N1115 Probiotic Supplement to Young Children
The aim of the study is to examine the intervening effects of N1115 Probiotic Supplement (containing Junlebao Lp. N1115) on gut development in young children at the age of 6 month to 3 years by the way of a randomised…
- Trial name
- N1115Baby (NCT03416595)
- Testing
- N1115 Probiotic Supplement
- Where
- Ireland
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Junlebao Dairy Group Co., Ltd.
Cervical Degenerative Disc Disease
Study of Safety & Effectiveness of PRESTIGE® LP Cervical Disc vs. Anterior Cervical Fusion in Cervical DDD
The purpose of this clinical trial is to evaluate the safety and effectiveness of the PRESTIGE® LP Cervical Disc as a method of treating patients with symptoms of cervical degenerative disc disease at a single level from C3-C4 to…
- Trial name
- NCT00667459
- Testing
- PRESTIGE® LP Cervical Disc, ATLANTIS Anterior Cervical Plate
- Where
- 16 sites in United States
- Volunteers
- 280 people
- Sponsor
- Medtronic Spinal and Biologics
Chronic Kidney Disease Stage 3B, Chronic Kidney Disease stage4
Low-Protein Diet With Low-Protein Foods Versus a LPD Without LP Foods in Patients With Chronic Kidney Disease (CKD)
The KDOQI 2020 - Clinical practice guideline for nutrition in chronic kidney disease (CKD) -recommends protein restriction to reduce the risk of end-stage renal disease/death and improve quality of life, a low protein diet…
- Conditions
- Chronic Kidney Disease Stage 3B, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 5, Chronic Kidney Disease Stage 3A
- Trial name
- NCT05489120
- Testing
- Consumption of FLAVIS
- Where
- 18 sites in France
- Volunteers
- 210 people
- Sponsor
- Dr. Schär AG / SPA
Cardiovascular Risk, LDL-C
Impact of the Corrie Lipids Digital Health Program on Lipid Optimization
The overall objective is to evaluate the effectiveness and implementation of the Corrie Lipids Program, a comprehensive digital health initiative designed to address critical gaps in lipid-lowering as a component of ASCVD…
- Conditions
- Cardiovascular Risk, LDL-C, Lipids, Digital Health
- Trial name
- NCT07478887
- Testing
- Corrie Lipids Digital Health Program
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Johns Hopkins University
Cervical Degenerative Disc Disease, Radiculopathy
Study of the Safety and Effectiveness of the Artificial Cervical Disc - Low Profile Device at Two Adjacent Levels
The purpose of this clinical investigation is to assess the safety and effectiveness of using the PRESTIGE-LP device in the treatment of patients with symptomatic degenerative disc disease at two adjacent levels of the cervical…
- Conditions
- Cervical Degenerative Disc Disease, Radiculopathy, Myelopathy
- Trial name
- NCT00637156
- Testing
- PRESTIGE LP device at two adjacent levels, Bi-level fusion with ATLANTIS Cervical Plate System
- Where
- 29 sites in United States
- Volunteers
- 397 people
- Sponsor
- Medtronic Spinal and Biologics
Atherosclerosis
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or stroke) in people with coronary heart disease.
- Trial name
- STABILITY (NCT00799903)
- Testing
- Darapladib
- Where
- 650 sites in United States, Argentina and 37 more
- Volunteers
- 15,828 people
- Sponsor
- GlaxoSmithKline
Fasting
Bioequivalence Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg Under Fasting Conditions
This is a randomized, open Label, balanced, two-treatment, two-period, two-sequence, single dose, cross over pivotal study. The purpose of this study is to assess the bioequivalence between Test Product and the corresponding…
- Trial name
- NCT01831700
- Testing
- Lisinopril and Hydrochlorothiazide Tablets (20+25) mg, Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets
- Where
- India
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- IPCA Laboratories Ltd.
Cholesterol; Metabolic Disorder, Lipoproteinemia
Kinetic Study of Lp(a) and PCSK9 in Humans
The aim is to study the relationship between lipoprotein(a) [Lp(a)] and PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9) in humans with a kinetic study of lipoproteins in patients with dramatic increase of Lp(a) and controls.
- Trial name
- HuLaUP (NCT04247048)
- Testing
- infusion of tracer [5,5,5-2H3] -L-leucine
- Where
- France
- Volunteers
- 21 people
- Sponsor
- Nantes University Hospital
Coronary Artery Disease
Lp(a) With CCTA Assessed Parameters and Clinical Outcomes
Lipoprotein(a) [Lp(a)] is a risk factor for cardiovascular events, although the underlying mechanism remains unclear. This study evaluated the relationship between Lp(a) and high-risk attributes (HRA) by coronary computed…
- Trial name
- CHART-ACCORD (NCT05323227)
- Testing
- Coronary CTA
- Where
- China
- Volunteers
- 378 people
- Sponsor
- Shanghai Zhongshan Hospital
Atherosclerotic Cardiovascular Disease
Pelacarsen Roll-over Extension Program
This non-randomized, rollover extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed either of the double-blind parent studies (CTQJ230A12303 or CTQJ230A12304).
- Trial name
- NCT06875973
- Testing
- Pelacarsen (TQJ230)
- Where
- 89 sites in United States, Puerto Rico
- Volunteers
- 599 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Periodontitis (Disorder)
Serum Lipid Levels and Lp-PLA2 in Chronic Periodontitis
To assess the association between periodontal parameters, serum lipid profile and Lp-PLA2 level in systemically healthy Chronic Periodontitis subjects and healthy controls.
- Trial name
- NCT03041480
- Testing
- serum lipid levels and Lp-PLA2
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Meenakshi Ammal Dental College and Hospital
Pacemaker
A Safety and Effectiveness Monitoring in France for AVEIR VR LP and AVEIR AR LP (France LEADLESS)
Although the idea of a leadless pacemaker was first proposed in the 1970s to eliminate the probes, pockets and connectors required by conventional cardiac procedures and the associated complications, the first devices were not…
- Trial name
- FranceLEADLESS (NCT06262295)
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- French Cardiology Society
Elevated Lp(a)
A Study on the Effects of TA-8995 on Lp(a) in Subjects With Elevated Lp(a)
A study in males and females with elevated Lp(a) to look at the effects of TA-8995 on Lp(a) levels.
- Trial name
- NCT02241772
- Testing
- TA-8995
- Where
- Denmark
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Xention Ltd
Elevated Lipoprotein(a), Cardiovascular Disease
Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease
This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 681257 and to assess the efficacy of different doses and dosing regimens of ISIS…
- Trial name
- NCT03070782
- Testing
- ISIS 681257
- Where
- 32 sites in United States, Canada and 3 more
- Volunteers
- 286 people
- Sponsor
- Akcea Therapeutics
Amputation
Junior LP Foot - Clinical Investigation Protocol
The purpose of the following study is of exploratory nature to provide design input for a prosthetic foot under development for children with lower limb loss, amputation or deficiency.
- Trial name
- NCT06156839
- Testing
- Prosthetic Foot
- Volunteers
- 13 people
- Sponsor
- Össur Iceland ehf
Cardiovascular Disease
Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study
Evaluate the effect of olpasiran administered subcutaneously (SC) compared with placebo, on percent change from baseline in lipoprotein(a) (Lp[a]).
- Trial name
- NCT04270760
- Testing
- Olpasiran
- Where
- 36 sites in United States, Australia and 5 more
- Volunteers
- 281 people
- Sponsor
- Amgen